RT Journal Article
SR Electronic
T1 ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.21250285
DO 10.1101/2021.01.22.21250285
A1 Marcolungo, Luca
A1 Beltrami, Cristina
A1 Esposti, Chiara Degli
A1 Lopatriello, Giulia
A1 Piubelli, Chiara
A1 Mori, Antonio
A1 Pomari, Elena
A1 Deiana, Michela
A1 Scarso, Salvatore
A1 Bisoffi, Zeno
A1 Grosso, Valentina
A1 Cosentino, Emanuela
A1 Maestri, Simone
A1 Lavezzari, Denise
A1 Iadarola, Barbara
A1 Paterno, Marta
A1 Segala, Elena
A1 Giovannone, Barbara
A1 Gallinaro, Martina
A1 Rossato, Marzia
A1 Delledonne, Massimo
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.22.21250285.abstract
AB We report Accurate SARS-CoV-2 genome Reconstruction (ACoRE), an amplicon-based viral genome sequencing workflow for the complete and accurate reconstruction of SARS-CoV-2 sequences from clinical samples, including suboptimal ones that would usually be excluded even if unique and irreplaceable. We demonstrated the utility of the approach by achieving complete genome reconstruction and the identification of false-positive variants in >170 clinical samples, thus avoiding the generation of inaccurate and/or incomplete sequences. Most importantly, ACoRE was crucial to identify the correct viral strain responsible of a relapse case, that would be otherwise mis-classified as a re-infection due to missing or incorrect variant identification by a standard workflow.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the competent Ethical Committee for Clinical Research of Verona and Rovigo Provinces (Prot N 39528/2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall fastq data have been upload to the repository http://ddlab.sci.univr.it/files/SARS-CoV2_Paper/SARS-CoV2_Paper.tar